Hantz Financial Services Inc. Sells 2,212 Shares of Novo Nordisk A/S (NYSE:NVO)

Hantz Financial Services Inc. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 182,775 shares of the company’s stock after selling 2,212 shares during the quarter. Hantz Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $21,763,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Tidal Investments LLC raised its holdings in Novo Nordisk A/S by 13.1% during the 1st quarter. Tidal Investments LLC now owns 4,146 shares of the company’s stock valued at $532,000 after buying an additional 481 shares during the last quarter. Burney Co. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $243,000. Cetera Investment Advisers raised its holdings in Novo Nordisk A/S by 453.3% during the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after buying an additional 217,545 shares during the last quarter. Cetera Advisors LLC raised its holdings in Novo Nordisk A/S by 106.8% during the 1st quarter. Cetera Advisors LLC now owns 63,633 shares of the company’s stock valued at $8,170,000 after buying an additional 32,862 shares during the last quarter. Finally, Cetera Advisor Networks LLC raised its holdings in Novo Nordisk A/S by 24.4% during the 1st quarter. Cetera Advisor Networks LLC now owns 170,897 shares of the company’s stock valued at $21,943,000 after buying an additional 33,482 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $106.13 on Friday. The firm’s 50-day moving average price is $113.22 and its 200-day moving average price is $128.18. The company has a market capitalization of $476.26 billion, a PE ratio of 34.35, a P/E/G ratio of 1.37 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.